Biotech Giant Amgen Sues Colorado for Moving to Control Enbrel Pricing

Multinational biotech Amgen, based in Southern California, maker of the blockbuster arthritis drug Enbrel, recently sued the State of Colorado over a state board’s efforts to possibly cap the price of the drug.  While incomes of households become ever more polarized in America, meaning growing numbers of people will struggle to pay for basic medicines. Hence the trend at the federal and state level to drive down drug costs.

This specific lawsuit, filed Friday in U.S. District Court in Denver, has Amgen arguing that the actions of Colorado’s Prescription Drug Affordability Board are unconstitutional because they conflict with federal laws and because they violate rights to due process.